Back to top
more

Cellectis (CLLS)

(Delayed Data from NSDQ)

$2.55 USD

2.55
11,743

+0.08 (3.24%)

Updated Apr 19, 2024 04:00 PM ET

After-Market: $2.52 -0.03 (-1.18%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Iovance's (IOVA) Q3 Earnings Beat Estimates, Revenues Nil

by Zacks Equity Research

Iovance Biotherapeutics (IOVA) reports a wider-than-expected loss in Q3. The company is on track to initiate a rolling BLA submission for lifileucel in melanoma later this month.

Iovance (IOVA) Doses First Patient in TIL Cancer Therapy Study

by Zacks Equity Research

Iovance (IOVA) doses the first patient in phase I/II study evaluating its TIL therapy candidate, IOV-4001, in adults with metastatic melanoma and NSCLC.

Iovance (IOVA) Focuses on Seeking Nod for Melanoma Therapy

by Zacks Equity Research

Iovance (IOVA) is progressing with its pipeline development. Management, after many delays, initiated a rolling BLA filing with the FDA for its lead candidate in metastatic melanoma.

Iovance (IOVA) Q2 Earnings Miss, Lifileucel BLA on Track

by Zacks Equity Research

Iovance Biotherapeutics (IOVA) reports a wider-than-expected second-quarter loss. The company is on track to initiate a rolling BLA submission for lifileucel in melanoma later this month.

Strength Seen in Immatics (IMTX): Can Its 18% Jump Turn into More Strength?

by Zacks Equity Research

Immatics (IMTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Seer, Inc. (SEER) Stock Jumps 12.9%: Will It Continue to Soar?

by Zacks Equity Research

Seer, Inc. (SEER) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Iovance (IOVA) Pipeline Aids Growth Amid Lack of Marketed Drugs

by Zacks Equity Research

Iovance (IOVA) is progressing well with the clinical development of its pipeline candidates. It expects to file a BLA with the FDA, seeking approval for its lead candidate to treat metastatic melanoma, this August.

Iovance (IOVA) Stock Rallies 33% in a Month: Here's Why

by Zacks Equity Research

Iovance (IOVA) to complete the FDA filing for its lead candidate in melanoma by August. It will start a clinical study for its first TALEN-edited TIL therapy for two advanced cancer indications later this year.

Allogene (ALLO) Focuses on Pipeline Amid Lack of Marketed Drugs

by Zacks Equity Research

With no product revenues due to the lack of marketed drugs, Allogene (ALLO) focuses on developing its pipeline candidates that mainly consist of allogenic CAR T therapies.

Iovance (IOVA) to Start Clinical Studies for TIL Therapy

by Zacks Equity Research

Iovance (IOVA) gets FDA nod to start clinical study for IOV-4001, which utilizes the technology licensed from Cellectis. A clinical study in melanoma or NSCLC indication is expected to begin in 2022.

Iovance (IOVA) Announces Wider-Than-Anticipated Q4 Loss

by Zacks Equity Research

Iovance Biotherapeutics' (IOVA) fourth-quarter loss is wider than expected. The company is on track to file regulatory submission for lifileucel in melanoma by first-half 2022.

Allogene (ALLO) Clinical Hold on CAR-T Studies Removed by FDA

by Zacks Equity Research

The FDA removes the hold on Allogene's (ALLO) clinical studies evaluating AlloCAR T therapy candidates after investigations confirmed that there is no chromosomal abnormality in its candidates.

Iovance (IOVA) Reports Wider-Than-Anticipated Loss in Q3

by Zacks Equity Research

Iovance Biotherapeutics' (IOVA) third-quarter loss is wider than expected. The company is progressing well in terms of development of pipeline candidates.

Iovance (IOVA) Q2 Earnings Miss Estimates, Pipeline in Focus

by Zacks Equity Research

Iovance's (IOVA) second-quarter loss is wider than expected. The company is progressing well in terms of development of its pipeline candidates.

Allogene (ALLO) Multiple Myeloma Candidate Gets Fast Track Tag

by Zacks Equity Research

Allogene's (ALLO) next-generation allogeneic CAR T therapy, ALLO-605, gets Fast Track designation from the FDA to treat patients with relapsed or refractory multiple myeloma.

Cellectis (CLLS) Jumps: Stock Rises 9%

by Zacks Equity Research

Cellectis (CLLS) saw a big move last session, as its shares jumped 9% on the day, amid huge volumes.

The Zacks Analyst Blog Highlights: Emergent BioSolutions, Vertex Pharmaceuticals, Editas Medicine, Cellectis and Thermo Fisher

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Emergent BioSolutions, Vertex Pharmaceuticals, Editas Medicine, Cellectis and Thermo Fisher

Booming Gene Editing Market to Pep Up These 5 Biotech Stocks

by Zacks Equity Research

Advancements in gene editing have boosted the biotech space, putting the spotlight on five stocks that can make the most.

Is Cellectis (CLLS) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (CLLS) Outperforming Other Medical Stocks This Year?

Moving Average Crossover Alert: Cellectis

by Zacks Equity Research

Cellectis S.A. (CLLS) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Is Cellectis (CLLS) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (CLLS) Outperforming Other Medical Stocks This Year?

Cellectis' Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Cellectis.

How Cellectis (CLLS) Stock Stands Out in a Strong Industry

by Zacks Equity Research

Cellectis (CLLS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Top Ranked Momentum Stocks to Buy for May 12th

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, May 12th.

What Makes Cellectis S.A. (CLLS) a New Strong Buy Stock

by Zacks Equity Research

Cellectis S.A. (CLLS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.